New drug litfulo tracked in 3,000 patients for hair loss treatment
NCT ID NCT07152119
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is monitoring the safety and effectiveness of Litfulo (Ritlecitinib) in 3,000 people with severe alopecia areata, a condition causing patchy hair loss. Participants take the drug as prescribed in real-world clinics across Korea. Researchers will track side effects and hair regrowth over 48 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Litfulo (Ritlecitinib)
- What this could lead to
- If successful, this study could confirm that Litfulo is a safe and effective treatment for severe alopecia areata in adults and teens.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. Side effects are possible, and not everyone may respond to treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE ALOPECIA AREATA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill could regrow hair in severe alopecia – trial begins
- New antibody drug aims to halt skin and hair loss
- New analysis explores how patients and doctors view ritlecitinib for severe hair loss
- New pill could help kids with severe hair loss regrow hair
- Hair loss drug ritlecitinib tested for Long-Term safety in teens